Gary Schwartz, MD


Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas

October 22nd 2020

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

Dr. Schwartz on Future Research Efforts in Sarcoma

October 15th 2020

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial

August 6th 2020

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Dr. Schwartz on the Updated Design of the Alliance A091401 Trial in Metastatic Sarcomas

July 31st 2020

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Dr. Schwartz on ​the Results of the Alliance A091401 Study in Metastatic Sarcoma

July 1st 2020

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Dr. Schwartz on the Results of the PACIFIC Trial

February 19th 2018

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).

Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma

June 19th 2015

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Combination of Cixutumumab and Temsirolimus Demonstrates Improved Progression-Free and Encouraging Overall Survival for Bone and Soft Tissue Sarcoma

August 29th 2013

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.